Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4Terminated 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 20Gastrointestinal 10Head & Neck 9CNS 9Genitourinary 6Tumor-Agnostic 5Sarcoma 5Endocrine 4Breast 4Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Breast Neoplasms 3Neoplasm Metastasis 1Advanced Breast Cancer 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × vandetanib × Breast × Clear all
NCT00494481 2016-09-30

E3 Breast Cancer Taxotere Combination

Sanofi

Phase 2 Completed
64 enrolled 7 charts
Breast

Advanced Breast Cancer

NCT00034918 2016-08-24

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

Sanofi

Phase 2 Completed
44 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00496665 2013-11-18

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
25 enrolled
Breast

Breast Neoplasms

NCT00811369 2013-11-18

ZAMBONEY

Ontario Clinical Oncology Group (OCOG)

Phase 2 Completed
126 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡